Li Wen1, Wei Jiang1, Meiqun Zhou1, Zhenxia Wu1. 1. Department of Rheumatology and Immunology, First People's Hospital Fuyang District, Hangzhou 311400, Zhejiang Province, China.
Abstract
OBJECTIVE: This study was designed to analyse the effect of combined application of iguratimod with methotrexate in the treatment of active rheumatoid arthritis (RA). METHODS: A total of 115 patients with active RA admitted to our hospital were enrolled and divided into group A (n=58) and group B (n=57) according to the method of random number table. Patients in group B were treated with methotrexate alone, while patients in group A were treated with methotrexate combined with iguratimod. The curative efficacy was compared between the two groups. RESULTS: At 6 months after treatment, the levels of CTX-1 and RANKL in group A were higher than those in group B, and the levels of OPG, IL-17 and TGF-α in group A were lower than those in group B (P<0.05). The level of Th17 cells in group A was higher than that in group B, and the level of Treg cells in group A was lower than that in group B at 6 months after treatment (P<0.05). Tender joints count, swollen joints count and DAS28 score in group A were less than those in group B at 6 months after treatment (P<0.05). The duration of morning stiffness of the joints and the score of joint pain degree in group A were less than those in group B at 1, 2, 3, 4, 5, and 6 months after treatment (P<0.05). CONCLUSION: The combined application of methotrexate and iguratimod in the treatment of active RA can effectively improve bone metabolism, regulate the levels of Th17 and Treg cells, play a prominent role in anti-inflammatory effect, and relieve symptoms, and thus achieve a more satisfactory curative effect. AJTR
OBJECTIVE: This study was designed to analyse the effect of combined application of iguratimod with methotrexate in the treatment of active rheumatoid arthritis (RA). METHODS: A total of 115 patients with active RA admitted to our hospital were enrolled and divided into group A (n=58) and group B (n=57) according to the method of random number table. Patients in group B were treated with methotrexate alone, while patients in group A were treated with methotrexate combined with iguratimod. The curative efficacy was compared between the two groups. RESULTS: At 6 months after treatment, the levels of CTX-1 and RANKL in group A were higher than those in group B, and the levels of OPG, IL-17 and TGF-α in group A were lower than those in group B (P<0.05). The level of Th17 cells in group A was higher than that in group B, and the level of Treg cells in group A was lower than that in group B at 6 months after treatment (P<0.05). Tender joints count, swollen joints count and DAS28 score in group A were less than those in group B at 6 months after treatment (P<0.05). The duration of morning stiffness of the joints and the score of joint pain degree in group A were less than those in group B at 1, 2, 3, 4, 5, and 6 months after treatment (P<0.05). CONCLUSION: The combined application of methotrexate and iguratimod in the treatment of active RA can effectively improve bone metabolism, regulate the levels of Th17 and Treg cells, play a prominent role in anti-inflammatory effect, and relieve symptoms, and thus achieve a more satisfactory curative effect. AJTR
Authors: Sujith Subesinghe; Katie Bechman; Andrew I Rutherford; David Goldblatt; James B Galloway Journal: J Rheumatol Date: 2018-03-15 Impact factor: 4.666
Authors: Marco Infante; Alessandra Fabi; Francesco Cognetti; Stefania Gorini; Massimiliano Caprio; Andrea Fabbri Journal: J Exp Clin Cancer Res Date: 2019-01-08
Authors: Denis Mongin; Kim Lauper; Carl Turesson; Merete Lund Hetland; Eirik Klami Kristianslund; Tore K Kvien; Maria Jose Santos; Karel Pavelka; Florenzo Iannone; Axel Finckh; Delphine Sophie Courvoisier Journal: RMD Open Date: 2019-10-17